Abstract:Abstract Introduction Burn patients have altered pharmacokinetics, in part, due to a high incidence of augmented renal clearance (ARC). Augmented renal clearance is associated with subtherapeutic antibiotic concentrations necessitating dosing regimens that are greater than FDA approved doses. The objective of this cohort analysis was to assess antibiotic concentrations in patients with ARC specifically when real-time therapeutic drug monitoring was not available for the antibiotic. Methods This retrospective descriptive cohort was performed at an ABA verified burn center. All patients with an antibiotic serum concentration measured between 2/2022 and 7/2023 and confirmed ARC were included. Patients were excluded if the only antibiotic concentration available was an aminoglycoside or vancomycin. Results In all, 10 patients (90% male) had 15 non-real time antibiotic concentration assessments. The median (range) age, weight, TBSA, day since injury, serum creatinine and urine collection creatinine clearance corresponding to the drug concentration were 38 years (18-53), 85 kg (51-190), 24% (3-68.25), 13 days (6-32), 0.77 mg/dL (< 0.2-1.53), and 200 mL/min (96-336), respectively. The most common antibiotic concentration assessed was piperacillin (PIP, n=9), followed by meropenem (MER, n=3), cefepime (n=2), and linezolid (n=1). Piperacillin/tazobactam was administered as 22.5g/day continuous infusion and resulted in a median (range) PIP concentration of 43.7 mg/L (25-117). A single outlier of 117 mg/L occurred in a patient who was no longer in ARC, but reexhibited ARC days later and had a follow-up PIP concentration of 32 mg/L. Two MER concentrations representing a 2g every 8 hours using a 6 hour infusion were 13.9 mg/L at the end of infusion and 7.3 mg/L one hour after infusion. MER 1g every 8 hours with a 3 hour extended infusion resulted in a trough concentration of 1.2 mg/L. Cefepime 2g every 6 hours with a 3 hour extended infusion resulted in a peak and trough of 43.8 and 29.6 mg/L. Linezolid 600mg orally every 8 hours resulted in a trough of 4.21 mg/L. No adverse events were identified. Conclusions Burn patients with ARC may require more aggressive dosing regimens to reach adequate antibiotic concentrations. A large prospective study is required to identify appropriate antibiotic dosing strategies to overcome pharmacokinetic alterations in this population, especially in the setting of pathogens with high minimum inhibitory concentrations. Applicability of Research to Practice Although antibiotic target concentrations have not been established in the burn population, this cohort suggests antimicrobial regimens should be adjusted in burn patients with ARC. The lack of timely therapeutic drug monitoring for most antimicrobials may hamper patient specific dosing regimens to adequately treat infectious pathogens with elevated minimum inhibitory concentrations.

Augmented Renal Clearance: What Have We Known and What Will We Do?

Individualized antibiotic dosage regimens for patients with augmented renal clearance

Prevalence and Risk Factors of Augmented Renal Clearance: A Systematic Review and Meta-Analysis

LC-MS/MS-Based Serum Metabolomics and Transcriptome Analyses for the Mechanism of Augmented Renal Clearance

The Impact of Augmented Renal Clearance on Vancomycin Pharmacokinetics and Pharmacodynamics in Critically Ill Patients

Augmented renal clearance in Chinese intensive care unit patients after traumatic brain injury: a cross-sectional study

Association between Augmented Renal Clearance and Inadequate Vancomycin Pharmacokinetic/Pharmacodynamic Targets in Chinese Adult Patients: A Prospective Observational Study

Scoping review of augmented renal clearance in critically ill pediatric patients

The Relationship between Uric Acid and the Development, Complication, and Prognosis of Atrial Fibrillation: The Views from a Clinical Study

Interplay Between Chronic Kidney Disease (CKD) and Upper Tract Urothelial Carcinomas (UUC): Foe or Friend?

Predictors of Augmented Renal Clearance in a Heterogeneous ICU Population as Defined by Creatinine and Cystatin C

Increased β-Lactams dosing regimens improve clinical outcome in critically ill patients with augmented renal clearance treated for a first episode of hospital or ventilator-acquired pneumonia: a before and after study

Population Pharmacokinetic Modeling and Dose Optimization of Vancomycin in Chinese Patients with Augmented Renal Clearance

Effect of renal clearance on vancomycin area under the concentration-time curve deviations in critically ill patients

Effects of augmented renal clearance on the outcome of vancomycin /norvancomycin

Clinical Outcomes of Protocolized Antibiotic Dosing in Critically Ill Surgical Patients With Bacteremia and Augmented Renal Clearance Compared With Critically Ill Surgical Patients Without Augmented Renal Clearance

510 Antibiotic Serum Concentrations in Burn Patients with Augmented Renal Clearance and Adjusted Regimens

Clinical study of vancomycin for appropriate dosing in severe infective patients with augmented renal clearance

A Descriptive Pharmacokinetic/pharmacodynamic Analysis of Ceftazidime‐avibactam in a Case Series of Critically Ill Patients with Augmented Renal Clearance

Acute Respiratory Distress Syndrome: Bench-to-Bedside Approaches to Improve Drug Development.

Unveiling the Mysteries of Contrast-Induced Acute Kidney Injury: New Horizons in Pathogenesis and Prevention